Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335021 · ClinicalTrials.gov registry record · NA
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults
A NA study of Insulin Resistance and Impairment of Oral Perception, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT02335021: Completed NA study of Insulin Resistance and Impairment of Oral Perception, sponsored by Yale University.
NCT02335021 is a NA study of Insulin Resistance and Impairment of Oral Perception that has completed, run by Yale University. The registered enrollment target is 97 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02335021, a NA study of Insulin Resistance and Impairment of Oral Perception, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effects of dietary exposure to artificial sweeteners on taste sensitivity, preference and brain response in adults. The investigators hypothesize that dietary exposure to artificial sweeteners (sucralose) will decrease sensitivity to taste, shift preference of sweet and savory taste to a higher dose, and reduce brain response in amygdala to sweet taste compared to sucrose.
Primary Outcome
general labeled magnitude scale ratings of taste intensity
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Sucrose
- DIETARY_SUPPLEMENT Sucralose
- DIETARY_SUPPLEMENT Sucralose + maltodextrin
- DIETARY_SUPPLEMENT Sucralose + Sucrose
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2015-01-01 |
| Est. Completion | 2019-04-24 |
| Phase | NA |
What the finished NCT02335021 record still lists
NCT02335021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 4 interventions - of which Sucrose is the first listed.
NCT02335021 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02335021 about?
NCT02335021 is a clinical study titled "The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults". The purpose of this study is to investigate the effects of dietary exposure to artificial sweeteners on taste sensitivity, preference and brain response in adults. The investigators hypothesize that dietary exposure to artificial sweeteners (sucralose) will decrease sensitivity to taste, shift prefe...
What is the current status of trial NCT02335021?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2015-01-01. Estimated completion is 2019-04-24.
What conditions does trial NCT02335021 study?
This clinical trial studies the following conditions: Insulin Resistance, Impairment of Oral Perception.
What interventions are being tested in trial NCT02335021?
The interventions under investigation include: Sucrose (DIETARY_SUPPLEMENT), Sucralose (DIETARY_SUPPLEMENT), Sucralose + maltodextrin (DIETARY_SUPPLEMENT), Sucralose + Sucrose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02335021?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02335021 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02335021's enrollment target sits among peer trials
97 30th of 120 higher than 91 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI